Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.61 |
| ▸ | TK1 | P04183 | 6/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11986879 | 1.00 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL2327879 | 1.00 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL31227958 | 1.00 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL32668971 | 1.00 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL13948025 | 1.00 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL1827369 | 1.00 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL4278968 | 1.00 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL12969271 | 1.00 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL22143532 | 1.00 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL4495987 | 0.94 | RNASE1 (0.64) | RNASE1TK1ABCG2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1466004-A1 | PROCESS FOR THE SELECTIVE ENZYMATIC HYDROLYSIS OF NUCLEOSIDE POLYESTERS | Innovate Biotechnology S.R.L. (IT) | 2004-10-13 | — | — | EP | claimed |
| WO-2003057894-A1 | PROCESS FOR THE SELECTIVE ENZYMATIC HYDROLYSIS OF NUCLEOSIDE POLYESTERS | INNOVATE BIOTECHNOLOGY S.R.L. (IT) | 2003-07-17 | — | — | WO | claimed |
| WO-2024186176-A1 | METHOD FOR PREPARING MODIFIED NUCLEOSIDES FROM THYMIDINE | 주식회사 압타머사이언스 | 2024-09-12 | — | — | WO | disclosed |
| US-8877734-B2 | Seleny-methyluracil compounds, radiosensitizer and pharmaceutical composition using them | KONGJU NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2014-11-04 | — | — | US | disclosed |
| US-20140065676-A1 | STACKING NUCLEIC ACID AND METHODS FOR USE THEREOF | QUANTIBACT A/S (DK) | 2014-03-06 | — | — | US | disclosed |
| US-20130211067-A1 | NOVEL SELENY-METHYLURACIL COMPOUNDS, RADIOSENSITIZER AND PHARMACEUTICAL COMPOSITION USING THEM | KONGJU NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2013-08-15 | — | — | US | disclosed |
| WO-2012050264-A1 | NOVEL SELENY-METHYLURACIL COMPOUNDS, RADIOSENSITIZER AND PHARMACEUTICAL COMPOSITION USING THEM | KONGJU NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION (KR) | 2012-04-19 | — | — | WO | disclosed |
| US-20090105186-A1 | Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2009-04-23 | — | — | US | disclosed |
| US-7169765-B1 | Acyl deoxyribonucleoside derivatives and uses thereof | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| US-20060217345-A1 | Beta-L-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2006-09-28 | — | — | US | disclosed |
| EP-1466004-A1 | PROCESS FOR THE SELECTIVE ENZYMATIC HYDROLYSIS OF NUCLEOSIDE POLYESTERS | Innovate Biotechnology S.R.L. (IT) | 2004-10-13 | — | — | EP | disclosed |
| US-6297222-B1 | TREATING OR PREVENTING RADIATION, MUTAGEN AND SUNLIGHT-INDUCED BIOLOGICAL DAMAGE, AND METHODS FOR IMPROVING WOUND HEALING AND TISSUE REPAIR | PRO-NEURON, INC. | 2001-10-02 | — | — | US | disclosed |
| US-6103701-A | ADMINISTERING COMPOSITIONS COMPRISING ACYL DERIVATIVES OF 2'-DEOXYRIBONUCLEOSIDES; FOR IMPROVING WOUND HEALING AND TISSUE REPAIR | VON BORSTEL REID WARREN (US) | 2000-08-15 | — | — | US | disclosed |
| US-6020322-A | Acyl deoxyribonucleoside derivatives and uses thereof | PRO-NEURON, INC. (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0683171-B1 | A process for the preparation of beta-thymidine | COUNCIL SCIENT IND RES (IN) | 1998-12-23 | — | — | EP | disclosed |
| US-5596087-A | Process for the preparation of beta thymidine | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 1997-01-21 | — | — | US | disclosed |
| EP-0355131-B1 | ACYL DEOXYRIBONUCLEOSIDE DERIVATIVES AND USES THEREOF | PRO NEURON INC (US) | 1996-09-04 | — | — | EP | disclosed |
| EP-0712629-A1 | Acyl deoxyribonucleoside derivatives and uses thereof | PRO-NEURON, INC. (US) | 1996-05-22 | — | — | EP | disclosed |
| EP-0683171-A1 | A process for the preparation of beta-thymidine | Council of Scientific and Industrial Research (IN) | 1995-11-22 | — | — | EP | disclosed |
| EP-0355131-A1 | ACYL DEOXYRIBONUCLEOSIDE DERIVATIVES AND USES THEREOF | PRO-NEURON, INC. (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130211067-A1 | NOVEL SELENY-METHYLURACIL COMPOUNDS, RADIOSENSITIZER AND PHARMACEUTICAL COMPOSITION USING THEM | SCLY, SELENOI, MGMT | RNASE1 851/4885TK1 2253/4885ABCG2 565/4885 |
| US-20090105186-A1 | Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | TYMP, ENTPD5, NUDT1 | RNASE1 224/4885TK1 102/4885ABCG2 1631/4885 |
| US-20060217345-A1 | Beta-L-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases | NTPCR, PNP, TYMP | RNASE1 62/4885TK1 11/4885ABCG2 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.